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Abstract
Purpose—Pancreatic adenocarcinomas (PAAD) often are not diagnosed until their late stages 
leaving no effective treatments. Currently immunotherapy provides a promising treatment option 
against this malignancy. However, a set of immunotherapy agents benefit patients with many types 
of cancer, but not PAAD. Sharing the origin in the same organ, diabetes and PAAD tend to occur 
concurrently. We aimed to identify the impact of diabetes on immunotherapy of PAAD by 
conducting a comparative genomics analysis.
Experimental Design—We analyzed levels 3 PAAD genomics data (RNAseq, miRNAseq, 
DNA methylation, somatic copy number and somatic mutation) from TCGA and Firehose. The 
differential molecular profiles in PAAD with/out diabetes were performed by the differential gene 
expression, pathway analysis, epigenetic regulation, somatic copy number alteration and somatic 
gene mutation.
Results—Differential gene expression analysis revealed a strong enrichment of immunogenic 
signature genes in diabetic individuals including PD-1 and CTLA4 that were currently targetable 
for immunotherapy. Pathway analysis further implied that diabetic individuals were defective in 
immune modulation genes. Somatic copy number aberration (SCNA) analysis showed a higher 
frequency of amplification and deletion occurred in the cohort without diabetes. Integrative 
analysis revealed strong association between differential gene expression and epigenetic 
regulations, however seemed not affected by SCNAs. Importantly, our somatic mutation analysis 
showed that the occurrence of diabetes in PAAD was associated with a large set of gene mutations 
encoding genes participating in immune modulation.
Conclusions—Our analysis reveals the impact of diabetes on immunodeficiency in PAAD 
patients and provides novel insights into new therapeutic opportunities.
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Introduction
Pancreatic cancer is the 4th leading cause of cancer-related death in USA. In 2017, an 
estimate of 53,670 patients will be diagnosed with pancreatic cancer in United State(1). 
Early detection of pancreatic cancer is difficult since cancer-specific symptoms occur only in 
the advanced stage resulting in a low 5-year survival rate of 8%(1). Of all types of pancreatic 
cancer, pancreatic adenocarcinoma (PAAD) is the most common. Treatment of PAAD is still 
a major challenge and surgery is the only curative therapy. However, only 15∼20% patients 
are suitable for resection and up to 80% of the individuals that undergo surgery will suffer 
relapse(2). Radiotherapy and chemotherapy have been shown to benefit individuals with 
PAAD and increase the overall survival rate; however survival is still very low(2). No 
therapeutic agent has provided long term benefit for patients who are not surgical 
candidates(2). Immunotherapy represents an exciting new anticancer therapy that recruits 
and activates the immune system to recognize tumor-specific antigens(3). Clinical trials of 
immunotherapy against PAAD have shown promising outcomes by increasing survival 
rate(4). Moreover, individuals with drug resistance were suitable for immunotherapy(5).
Diabetes is an endocrine disease ranking the 7th leading cause of death in USA. There is a 
significant association between diabetes and pancreatic cancer, although it is still under 
debate whether diabetes is a cause or a result of the malignancy(6). Current thinking regards 
diabetes as a risk factor for pancreatic cancer. Evidence to support this notion includes a 
large cohort study of 109,581 individuals hospitalized in Denmark showing that incidence 
ratio of diabetics developing pancreatic cancer is 2.1(7). The risk of developing pancreatic 
cancer is relatively higher for new onset diabetes, especially for older subjects(8). A meta-
analysis conducted in 1995 including 20 case-control and cohort studies between 1975 and 
1994 reported that the pooled relative risk of pancreatic cancer for diabetics to non-diabetics 
is 2.1(9). Another meta-analysis including 36 studies between 1996 and 2005 also 
demonstrates that diabetes is a risk factor for pancreatic cancer with the overall odds ratio of 
1.8(10).
In contrast, other studies do not show that diabetes is a risk factor, but rather is a 
consequence of pancreatic cancer. This comes from the observation that in a majority of 
subjects with pancreatic cancer (56.1%), diabetes is diagnosed concomitantly or 2 years 
before the diagnosis of cancer(11). Insulin sensitivity and diabetes metabolic control is 
improved in pancreatic cancer patients 3 months following surgery(12). The pancreatic 
cancer cell line MIA PaCa2 could induce hyperglycemia in immunodeficient mice and the 
diabetogenic agent was identified as a 14 amino acid peptides from N-terminal of 
S100A8(13, 14).
Genomics-scale technologies foster advances in the identification of a molecular profile in 
PAAD subjects. Exome sequencing and copy number analysis reveals a list of mutations 
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aggregating into multiple molecular pathways(15, 16). In the mutational landscape, KARS 
(Lysyl-tRNA synthetase), TP53 (tumor protein p53), SMAD4 (SMAD family member 4) 
and CDKN2A (cyclim-dependent kinase inhibitor 2A) are the four most common mutated 
genes, of which KARS mutation has the highest frequency and is almost ubiquitous(15, 17). 
Molecular mechanisms involved in the mutational profiles include activating mutations of 
KRAS, TGF-β signaling, WNT signaling, SWI-SNF complex, NOTCH signaling, disruption 
of G1/S transition, ROBO/SLIT signaling, histone modification, DNA damage repair and 
RNA processing(16). DNA copy number variation resulted in the genetic loss of tumor 
suppressor gene and increase copy number of oncogenes (MYC (c-Myc), KRAS and EGFR 
(epidermal growth factor receptor))(18). Explicit studies of genomics profiles have 
attempted to uncover the molecular aberrations in PAAD, however, despite the well-known 
association of diabetes in PAAD, the differential molecular profiles in PAAD with/out 
diabetes remain unknown. In this study, we examine the molecular signatures and find that 
PAAD with diabetes is accompanied by immunodeficiency indicating potential challenges 
for immunotherapy in this specific subgroup.
Materials and methods
Data resource
The Cancer Genome Atlas (TCGA) sponsored by National Cancer Institute is publicly 
available resource depositing multi-dimensional cancer genomics and clinical data set. We 
downloaded PAAD clinical information, level 3 genomics data (RNAseqV2, miRNASeq, 
DNA Methylation and somatic mutation data) from TCGA data portal (https://tcga-
data.nci.nih.gov/tcga/). SCNA data was downloaded from Firehose (http://
gdac.broadinstitute.org/). The data used in this study was the updated as of 8/15/2016. 
Clinical information and DNA methylation data were downloaded by TCGA Assembler(19). 
miRNASeq were downloaded by tcga2stat(20). Individuals with PAAD that had a history of 
diabetes were regarded as PAAD with diabetes while individuals with PAAD but without a 
history of diabetes were considered PAAD without diabetes. An independent RNAseq 
dataset with accession number of GSE79668 was downloaded from GEO database. 
GSE79668 dataset was originally used to conduct the association study between gene 
expression and long-term survival in pancreatic adenocarcinoma patients(21). We also 
download another independent microarray dataset (GSE15932) from GEO database to 
further validate our result. This microarray dataset was originally used to study the blood 
biomarkers of pancreatic cancer associated with diabetes(22).
Clinical information analysis
Clinical information was analyzed in R (version 3.2.0) and SAS 9.3 (SAS institute). Fisher's 
exact test was used to test significance in categorical data and logistic regression for 
continuous variable. Survival curves for PAAD with/out diabetes were plotted by Kaplan-
Meier method. The comparison of the survival curves was conducted by log rank test. A 
total of 38 PAAD with diabetes and 111 PAAD without diabetes patients deposited in TCGA 
data portal were used for the clinical information analysis.
Yan et al. Page 3
Clin Cancer Res. Author manuscript; available in PMC 2018 October 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Analysis of differential gene expression of RNAseq data and microarray data
Raw counts of gene expression from RNAseq deposited in TCGA data portal were used for 
the differential gene expression. The analysis was performed through edgeR package in 
R(23). edgeR examined the differential gene expression by accounting variability through an 
overdispersed Poisson model and moderating the degree of overdispersion by Empirical 
Bayes methods(23). In this study, CPM (count per million) was calculated through the 
program and only genes with CPM larger than 1 across at least 15 samples (10% of all 
samples) were considered. A generalized linear model plus likelihood ratio test were used to 
calculate the significance as well as the fold change (FC). The genes were considered as 
statistically significant when the adjusted p value was less than 0.05 and the absolute FC 
larger than 1.5. A total of 147 patients were analyzed, including 38 PAAD with diabetes and 
109 PAAD without diabetes. We performed the same strategy to analyze the differential 
gene expression in GSE79668 dataset. For GSE15932 microarray dataset, we used Wilcoxon 
rank-sum test to conduct the differential expression of each probe.
Gene set enrichment analysis(GSEA) of RNAseq data
To investigate potential biological pathways in subjects of PAAD with/without diabetes, we 
downloaded normalized gene expression data from TCGA data portal with RSEM (RNA-
Seq by Expectation-Maximization) values provided. The dataset for canonical pathways 
were downloaded from msigdb(24). The enrichment score as well as the significance were 
evaluated by GSEA 1.0(24). In this analysis, a total of 1320 gene sets were included. Only 
the gene sets with size not less than 15 genes were considered. A total number of 5000 
random permutations were performed to calculate p value. The pathways with false 
discovery rate (FDR) q-value less than 0.05 were considered as statistically significant. A 
total of 147 patients were analyzed, including 38 PAAD with diabetes and 109 PAAD 
without diabetes.
Analysis of somatic copy number aberration between PAAD with/out diabetes
SCNA data was downloaded from Firehose and split into the sets of PAAD with/out diabetes 
respectively. GISTIC 2.0 was used to conduct SCNA analysis(25). GISTIC 2.0 was a revised 
computational program to identify somatic copy number alteration by investigating the 
frequency and amplitude of observed events(25). GISTIC 2.0 investigated the significance of 
the amplification or deletion of the regions of the genome. In this study, the genes within the 
significant genomic regions were further analyzed to examine the overlay with those 
significantly differentially expressed as identified from RNAseq.
Integration of gene expression and epigenetic change
miRNASeq data deposited in TCGA data portal provided the miRNA stem-loop expression 
level as rpmmm (reads per million miRNA mapped). In this study, a total of 147 patients 
were analyzed for miRNA stem loop expression, including 38 PAAD with diabetes and 109 
PAAD without diabetes. To investigate the potential gene regulation by miRNA, we focused 
on miRNA (nmiRNA=44) with largest difference in PAAD with/out diabetes (here we 
selected absolute fold change larger than 1.2) and the significant differential gene selected 
from RNAseq. Since miRNASeq only provided the expression level of the stem loop, the 
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stem loop's expression level was considered as the mature miRNA. The relationship between 
miRNA and gene was analyzed by microRNA Target Filter module in Ingenuity Pathway 
Analysis (IPA). Pairs selected for further analysis showed i) the miRNA and gene in a 
negative relationship; ii) high prediction accuracy or iii) experimental evidence based on 
laboratory studies. The relationship between miRNA and gene was illustrated by network.
DNA methylation profile change could affect gene expression and this regulation was 
mostly modulated by methylation of CpG sites near the promoters. DNA methylation data 
was downloaded from TCGA data portal and average beta value of TSS200 (within 200 bp 
from transcription start sites) was calculated by TCGA Assembler(19). To integrate gene 
expression and DNA methylation profiles, we only focused on significantly differentially 
expressed genes as identified from RNAseq and then the gene's corresponding methylation 
profile. We conducted the differential correlation analysis by the transformed Pearson's 
correlation coefficient and permutation test(26). The details of the analysis were as follows: 
a) Pearson's correlation coefficients between gene and its corresponding methylation probe 
were calculated in PAAD with diabetes (Rwi_dia) and without diabetes (Rwo_dia) 
respectively; b) the Pearson's correlation coefficients were subjected to Fisher's z-
transformation as
Zwi dia =
1
2 ln [
1 + Rwi dia
1 − Rwi dia
] and Zwo dia =
1
2 ln [
1 + Rwo dia
1 − Rwo dia
] (1)
c) differential correlation between PAAD with diabetes and without diabetes was calculated 
as
Rdiff =
Nwi dia − 3
2 ∗ Zwi dia −
Nwo dia − 3
2 ∗ Zwo dia (2)
Here, Nwi_dia was the samples size of PAAD with diabetes and Nwo_dia denoted samples size 
of PAAD without diabetes; Zwi_dia and Zwo_dia was the transformed z values for PAAD with 
or without diabetes derived from equation (1). The statistical significance of differential 
correlation was assessed by 5000 permutation test by randomly shuffling the samples and P 
value less than 0.05 was considered as statistically significant.
Analysis of somatic mutation data
Mutation annotation format (MAF) files deposited in TCGA data portal for somatic 
mutation were downloaded for the analysis. In this study, the mutation occurred in only one 
or two samples was regarded as rare mutation and filtered out for further analysis. The 
number of mutant samples for each gene in each group was counted. Fisher's Exact test was 
used to analyze the association between mutation status and the occurrence of diabetes in 
PAAD. The log odds ratio was calculated to assess the risk of having diabetes if mutation 
was present. To avoid the zero or infinity issue in odd ratio, we added 0.5 to each cell of the 
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table having zero cell count. Benjamini-Hochberg method was used to adjust the multiple 
hypothesis testing (27). The mutations with adjusted p value less than 0.2, indicating that the 
result is likely to be valid 4 out of 5 times, were selected for further analysis. A total of 145 
patients were available for somatic mutation analysis, including 37 PAAD with diabetes and 
108 PAAD without diabetes.
Results
Patient characteristics
To characterize PAAD patients with/out diabetes, we first analyzed the clinical indices of 
these two groups of patients including age at initial pathologic diagnosis, maximum tumor 
dimension, gender, race, ethnicity, history of other malignancy, pathologic stage, smoking 
and alcohol history (Table 1). Within this 147 patient cohort, we did not find significant 
associations between occurrences of diabetes with any of the factors. Interestingly, we found 
that there was a trend toward being significant between smoking status and the occurrence of 
diabetes in PAAD (Table 1, p value=0.058). Consistent with what is reported by other 
groups, we did not observe a significant difference in the survival between diabetic and non-
diabetic patients (Fig. S1, p value=0.738)(28).
Differential gene expression profile in PAAD with/out diabetes
To investigate the differential gene expression pattern in PAAD with/out diabetes, we 
analyzed RNASeq data deposited in TCGA data portal by edgeR program(23). By setting 
the adjusted p value cutoff of 0.05 and the absolute fold change of 1.5, a total of 408 genes 
were significantly different (Fig. 1A, table S1). The number of genes over-expressed in 
diabetic subjects was almost two folds larger than that of down-regulated genes (Fig. 1A). 
The most significant gene was Thyroglobulin (TG) which was highly expressed in diabetic 
patients, showing a fold-change larger than 14. Diabetes is associated with various degrees 
of deterioration of thyroid function and the up-regulation of TG suggested thyroid 
dysfunction in PAAD with diabetes(29). We also observed that a large set of genes were 
strongly associated with immune modulation and some of them were the key genes targeted 
for immunotherapy. PD-1 (programmed death 1), an immunoinhibititory receptor expressed 
on various immune cells, including T cells, B cells, natural killer cells and tumor-infiltrating 
lymphocytes(30), was one of the immunotherapy targeted genes. In our study, we observed a 
highly up-regulation of this gene in PAAD with diabetes with FDR of 0.023 and fold change 
of 1.84 (Fig. 1B). Cytotoxic T-lymphocyte associated protein-4 (CTLA4), functioning as an 
immune checkpoint and another promising cancer immunotherapy target(31), was over-
expressed in PAAD with diabetes with FDR of 0.045(fold change: 1.71) (Fig. 1C). 
Chemokine (C-X-C motif) ligand 12 (CXCL12), restricting immune cells migration and the 
recognition of cancer antigens by creating a network of dense stroma (32), was up-regulated 
in diabetic subjects (FDR: 0.045; FC: 1.70; Fig. 1D). Indoleamine 2,3-dioxygenase (IDO), 
whose expression was up-regulated in PAAD with diabetes (FDR: 0.045; FC: 2.03; Fig. 1E), 
is an enzyme to catabolize tryptophan into kynurenine which inhibits T cell activation and 
stimulates regulatory T cell differentiation(33).
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The PANC-1 cell line was examined in vitro used conditions to mimic several aspects of 
PAAD with diabetes, the addition of 25mM glucose and10 nM insulin plus 0.4 mM 
palmitate bound to BSA. We found that this short 6 hr metabolic treatment in PANC-1 
increased gene expression of PD-1, CTLA4, CXCL12 and IDO, key genes identified from 
TCGA cohort. However, while there was an increase, statistical significance was not 
achieved (Fig. S2).
In addition to TCGA cohort, two independent datasets (GSE79668 and GSE15932) with 
diabetes were also identified to provide additional pancreatic adenocarcinoma samples. 
From GSE79668 RNAseq dataset, PD-1, CTLA4, CXCL12 and IDO were all highly 
expressed in PAAD with diabetes, validating our observations from the TCGA cohort (Fig. 
1B-1E). Even in the nucleated blood cells of individuals with pancreatic adenocarcinoma, 
the expression level of CTLA4 was significantly increased in diabetics (Fig. S3). IDO was 
also increased in diabetics, although it did not reach significant level (Fig. S3).
In addition to individual genes, the potential biological pathways affected by diabetes in 
PAAD were conducted by GSEA. Among 1320 canonical pathways, we observed a much 
larger number of pathways highly enriched in subjects of PAAD with diabetes (Fig. 1F). By 
setting significant FDR q value at 0.05, a total of 5 pathways were selected: hematopoietic 
cell lineage; primary immunodeficiency; T cell receptor signaling pathway; CD8 TCR 
pathway and NKT pathway (Fig. 1G). These 5 highly up-regulated pathways regulated 
immune cell development and function supporting the notion of dysfunction of immune 
system in subjects with PAAD and diabetes. Extending the number of pathways by setting 
FDR q value at 0.10, we found that 32 pathways were involved and these pathways were all 
up-regulated in diabetic subjects (Table 2).
Differential somatic copy number aberration in PAAD with/out diabetes
To explore the SCNA in PAAD with/out diabetes, we used GISTIC 2.0 to analyze the 
alteration of chromosome regions. A larger number of cytobands were significantly 
amplified in non-diabetic subjects, but only 8q24.13 and 18q11.2 were observed in the 
diabetic subgroup (Fig. 2A). Among the 22 chromosomes, significant copy number 
amplification was only observed in Chr1, 7, 8, 9, 12, 17, 18 and 19 (Fig. 2A). A total of 85 
genes were within the chromosome regions with significant copy number amplification in 
the non-diabetic subjects; however, the number of genes for PAAD with diabetes was 4 (Fig. 
2B). When these genes were overlaid with the significantly differentially expressed genes 
identified by RNAseq, 4 out of 85 genes (SPAG17, PGAP3, ERBB2, RMRP) within the 
amplification regions in non-diabetic subgroup showed the concordant expression pattern in 
RNAseq. This implied that the differential expression of these genes may be partially due to 
the copy number amplification (Fig. 2B). In PAAD without diabetes, a total of 18 
chromosome regions were identified as deletions (Fig. 2D). Two of them (9p21.3 and 
18q21.2) reached statistical significance in diabetic subjects (Fig. 2C). The chromosomes 
with significant deletion were Chr1, 4, 5, 6, 9, 12, 13, 16, 17, 18, 19 and 22 (Fig. 2C). The 
numbers of genes within the deletion in PAAD with/out diabetes were 5 and 2137 
respectively, with 3 of them occurred in both groups (Fig. 2D). Thirty-four genes in the non-
diabetic subgroup were also identified as statistically down-regulated, implying the gene 
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expression level may be partially due to the copy number variation (Fig. 2D). Although a 
small set of genes showed concordance between RNAseq and SCNA, regardless of 
amplification and deletion, the majority of the differentially expressed genes identified from 
RNAseq were not affected by SCNA, indicating the independence of gene expression and 
SCNA in PAAD with/out diabetes.
Integration of epigenetic and gene expression in PAAD with/out diabetes
Gene expression could be regulated by the expression of microRNAs (miRNAs). 
MicroRNAs are 19∼24nt small RNA that could bind to 3′UTR of the gene to induce the 
degradation of mRNA. Various diseases have been reported to be associated with the dys-
regulation of miRNA expression. In this study, we examined the potential regulation of gene 
expression by miRNA. The relationship between miRNA and its target gene was evaluated 
by microRNA Target Filter module in IPA. A total of 64 pairs were identified with 41 pairs 
having gene expression highly up-regulated in PAAD with diabetes (Fig. 3A). Among these 
pairs, hsa-miR-135-5p negatively regulated 7 genes. Each gene was negatively regulated by 
one or two miRNAs. There were nine genes of IGSF1, DCX, CACNA1A, CALN1, 
FAM23A, ZNF831, TRHDE, PPP1R16B and NR4A3 which were negatively regulated by 
two miRNAs (Fig. 3A). A set of genes responsible for immune modulation, such as 
CXCL12, TNFRSF13B (Tumor Necrosis Factor Receptor Superfamily Member 13B), IL16 
(Interleukin 16) and CXCR5 (C-X-C Motif Chemokine Receptor 5), were potentially 
regulated by miRNA expression. These pairs of miRNAs and genes from IPA were all based 
on prediction and further laboratory experimental validation will be needed.
Another epigenetic factor affecting gene expression is DNA methylation. DNA methylation 
occurred in the CpG island of promoters would suppress gene expression. Similar to 
miRNA, abnormal DNA methylation can lead to disease development and progression. To 
examine the gene regulation by DNA methylation in PAAD with/out diabetes, the 
differential correlation analysis was performed by transforming Pearson's correlation 
coefficients and permutation test. The majority of the correlation between DNA methylation 
and gene expression in either diabetic or non-diabetic subjects was negative (Fig. 3B). A 
permutation test identified 13 genes having differential correlation with the corresponding 
methylation status (Fig. 3B). One of the genes was ITGB7 (Integrin Subunit Beta 7), which 
showed no correlation in non-diabetic subjects (r2= -0.007), but a strong negative correlation 
in PAAD with diabetes (r2= -0.631) (Fig. 3C). The other interesting gene identified was 
SPAG6 (Sperm Associated Antigen 6) which is regarded as a novel target for cancer 
immunotherapy(34). We observed a weak negative correlation (r2= -0.287) in diabetic 
subjects, but a stronger correlation in non-diabetic subjects (r2= -0.615) (Fig. 3D). The 
differential correlation pattern implies that diabetes status in PAAD affects the regulation of 
gene expression by DNA methylation, suggesting that the diabetes status should be carefully 
considered when considering the treatment option for PAAD.
Somatic mutation analysis in PAAD with/out diabetes
Gene function is affected not only by its expression level and epigenetic regulation, but also 
by mutation status. Analysis of somatic mutation showed that there were considerably more 
mutational genes in diabetic subgroup compared to non-diabetic subjects (Fig.4A). By 
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setting the cutoff of false discovery rate less than 0.2, we identified a list of 28 mutational 
genes (Fig. 4B). These mutations all occurred in diabetic subjects indicating diabetes status 
in PAAD was associated with frequent gene mutations (Fig. 4B). Of these mutational genes, 
one gene (MAP2K4: Mitogen-Activated Protein Kinase Kinase 4) had the highest frequency 
which occurred in 4 out of 37 diabetic patients (Fig. 4B). MAP2K4, a tumor suppressor, is a 
member of the mitogen-activated protein kinase family and responsible for signal 
transduction to regulate various cellular process including proliferation, differentiation and 
development(35). Genetic inactivation of MAP2K4 in pancreatic cancer has been 
observed(35); here we found that the mutation of this gene exclusively occurred in the 
diabetes subgroup (Fig. 4B). A total of four missense and one splice mutation were observed 
in this gene (Fig. 4C). Importantly, we also observed that several genes encoding receptors 
were mutated in diabetic subjects (Fig. 4B). IL4R (Interleukin 4 Receptor), a type I cytokine 
receptor, could bind to IL4 and/or IL13 to stimulate immune response by antibody 
production and macrophages activation(36). The critical role of IL4R in tumor biology, 
tumor immunology and immunosurveillance rendered this gene an effective target for cancer 
therapy, including immunotherapy(36). We observed that this gene was mutated in diabetic 
subjects implying the toughness of this therapy in PAAD with diabetes (Fig. 4B). There 
were three mutations occurred for this molecule with two missense and one deletion (Fig. 
4C).
Discussion
Individuals suffering from diabetes are more likely to develop cancers of the liver, pancreas, 
endometrium, colon, rectum, breast and bladder(37, 38). Previously, studies have focused on 
the link between pancreatic cancer and diabetes, since these two diseases share their origin 
in the same organ. Although which of these two disease comes first when they are found in 
the same individual is still under active debate, it is clear that diabetes status impacts the 
clinical outcome by increasing tumor size and worsening the histological grade of the 
tumor(6, 39). Until this study, to our knowledge, the impact of genomics profiling in 
pancreatic cancer with/out diabetes was incomplete. Our study depicts these differential 
molecular alterations and provides a better understand for this complex disease.
Similar to other types of cancer, PAAD develops a set of mechanisms to avoid the 
recognition of the immune system(40). One of the mechanisms is over-expression of ligands 
to evade immunological checkpoints that may interrupt effector T cell responses(40). 
CTLA4 and PD-1 pathways are the two negative co-stimulatory pathways mediating 
immunosuppression in a diversity of cancer types, including melanoma, ovarian and lung 
cancers(41). In pancreatic cancer, over-expression of PDL-1 results in lymphocyte 
exhaustion, down-regulation of most MHC class I members, and is associated with shorter 
disease-free survival and overall survival(42). Moreover, PAAD is a heterogeneous disease 
involving types of molecular and cellular pathways. Bailey et. al. recently showed in a study 
of 456 PAAD subjects that the gene expression profiles fall into 4 subtypes: squamous, 
pancreatic progenitor, immunogenic and aberrantly differentiated endocrine exocrine(16). 
The immunogenic class was associated with an activated immune system including up-
regulation of B cells, CD4+ T cells, antigen presentation and CD8+ T cells (16). From our 
differential gene expression and pathway analysis, we found that PAAD with diabetes was 
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strongly associated with immunomodulation by up-regulating numerous immune pathways 
and stimulating cytokine production. The up-regulation of the immune system pattern we 
observed was consisted with that found by Bailey et al(16). Since Bailey et. al. did not 
include diabetes as one of the factors in the study, we suspected that the immunogenic class 
was derived from the subgroup of PAAD subjects with diabetes. Thus, we put forth that it 
may be more biologically meaningful to separate diabetic subjects for optimization of 
medical management especially for immunotherapy.
Another mechanism that could contribute to the immunosuppression observed in this cohort 
is abnormality in the antigen presentation. Continuous generation of tumor variants and/or 
alteration of antigen processing machinery by increased frequency of mutations can result in 
an escape of the tumor cells from recognition by the immune system(43). In addition, cancer 
microenvironment, a complex tissue consists of tumor cells as well as stromal cells, 
extracellular matrices, vasculature and inflammatory cells, results in immunosuppression by 
preventing effective lymphocyte priming and suppressing infiltrating effector cells. Over-
expression of CXCL12 stimulates fibroblast migration and proliferation and creates a dense 
network in cancer microenvironment to restrict immune cells migration to recognize cancer 
antigens (32). Up-regulation of IDO impairs immune clearance by creating a cancer 
microenvironment rich in immunosuppressive regulatory T cells but devoid of effector T 
cells (44). Besides CXCL12 and IDO, a large set of genes as well as mutations relevant to 
the antigen processing pathway and/or immune cell functions were observed in PAAD with 
diabetes. This provides additional insight into possible mechanisms of immune deficiency in 
this disease and proves the different biological behavior in diabetic subjects.
Discovery of immunosuppression in cancer has prompted the novel therapeutic approach of 
invoking the immune system to attack the tumor. Numerous immunotherapy treatments, 
including checkpoint inhibitors, cancer vaccine, adoptive therapy and monoclonal 
antibodies, have been proposed to cure pancreatic cancer(3). Some of these approaches have 
even been applied in clinical trials. However, these studies did not, or to a lesser extent, 
consider the co-occurrence of diabetes and the potential impact of diabetes for 
treatment(45-48). Based on our results, the immune deficiency caused by diabetes may 
influence the clinical outcomes. Two immunotherapy clinical trials against pancreatic cancer 
showed a partial response for anti-CTLA4 treatments(45, 48). Another phase I clinical trial 
of BMS-936559 using anti PDL-1 conducted in 2012 recruited 207 patients including 14 
pancreatic cancers. This study showed an objective response for melanoma, renal-cell 
cancer, non-small-cell lung cancer and ovarian cancer, but not pancreatic cancer(46). These 
clinical outcomes might be improved if the study took diabetes occurrence into 
consideration, since our data has shown an abnormally higher expression of both CTLA4 
(FDR: 0.045; fold change: 1.71) and PD-1(FDR: 0.023; fold change: 1.84) compared to the 
non-diabetic subjects. In addition, trials using vaccine immunotherapy and various 
monoclonal antibody treatments similarly resulted in a low percentage of response(49, 50). 
We could expect a high response rate to be observed if future trials could consider the 
presence of diabetes as one of the influential factors for immunotherapy.
In summary, for the first time to our knowledge, we conducted the differential molecular 
profile analysis in PAAD with/out diabetes and found that the disease features diverse modes 
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of genomic alteration, but not a single genetics component. Our findings through gene 
expression and pathway analysis showed a large set of up-regulated genes in PAAD with 
diabetes and the occurrence of diabetes was associated with immunodeficiency. Integration 
of gene expression and epigenetic changes reveal that regulation is at the levels of miRNA 
expression and DNA methylation. We analyzed the somatic mutation and found a high 
number of gene mutations in diabetic subjects and a large set of these mutated genes 
involved immune responses supporting the mechanism of immune deficiency in this 
subgroup.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We gratefully acknowledge contributions from TCGA research Network. We are grateful to Dr Chunying Yang at 
the Houston Methodist Research Institute for providing PANC-1 cell line.
Funding: These studies were partially supported by National Institutes of Health (NIH) - EY012601-17, 
EY007739-25, HL110170-05, EY023629-03 and EY025383-01A1 to MBG.
References
1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67:7–30. 
[PubMed: 28055103] 
2. Conroy T, Bachet JB, Ayav A, Huguet F, Lambert A, Caramella C, et al. Current standards and new 
innovative approaches for treatment of pancreatic cancer. Eur J Cancer. 2016; 57:10–22. [PubMed: 
26851397] 
3. Kotteas E, Saif MW, Syrigos K. Immunotherapy for pancreatic cancer. Journal of cancer research 
and clinical oncology. 2016; 142:1795–805. [PubMed: 26843405] 
4. Wang J, Reiss KA, Khatri R, Jaffee E, Laheru D. Immune Therapy in GI Malignancies: A Review. J 
Clin Oncol. 2015; 33:1745–53. [PubMed: 25918295] 
5. Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, et al. Allogeneic granulocyte 
macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with 
cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune 
activation. Clinical cancer research : an official journal of the American Association for Cancer 
Research. 2008; 14:1455–63. [PubMed: 18316569] 
6. Magruder JT, Elahi D, Andersen DK. Diabetes and pancreatic cancer: chicken or egg? Pancreas. 
2011; 40:339–51. [PubMed: 21412116] 
7. Wideroff L, Gridley G, Mellemkjaer L, Chow WH, Linet M, Keehn S, et al. Cancer incidence in a 
population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer 
Inst. 1997; 89:1360–5. [PubMed: 9308706] 
8. Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early 
diagnosis of pancreatic cancer. The Lancet Oncology. 2009; 10:88–95. [PubMed: 19111249] 
9. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. 
JAMA. 1995; 273:1605–9. [PubMed: 7745774] 
10. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M. Type-II 
diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005; 92:2076–83. 
[PubMed: 15886696] 
11. Gullo L, Pezzilli R, Morselli-Labate AM, Italian Pancreatic Cancer Study G. Diabetes and the risk 
of pancreatic cancer. N Engl J Med. 1994; 331:81–4. [PubMed: 8208269] 
Yan et al. Page 11
Clin Cancer Res. Author manuscript; available in PMC 2018 October 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
12. Permert J, Adrian TE, Jacobsson P, Jorfelt L, Fruin AB, Larsson J. Is profound peripheral insulin 
resistance in patients with pancreatic cancer caused by a tumor-associated factor? Am J Surg. 
1993; 165:61–6. discussion 6-7. [PubMed: 8380314] 
13. Basso D, Brigato L, Veronesi A, Panozzo MP, Amadori A, Plebani M. The pancreatic cancer cell 
line MIA PaCa2 produces one or more factors able to induce hyperglycemia in SCID mice. 
Anticancer Res. 1995; 15:2585–8. [PubMed: 8669828] 
14. Basso D, Greco E, Fogar P, Pucci P, Flagiello A, Baldo G, et al. Pancreatic cancer-derived S-100A8 
N-terminal peptide: a diabetes cause? Clin Chim Acta. 2006; 372:120–8. [PubMed: 16678810] 
15. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, et al. Pancreatic 
cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012; 491:399–405. 
[PubMed: 23103869] 
16. Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, et al. Genomic analyses 
identify molecular subtypes of pancreatic cancer. Nature. 2016; 531:47–52. [PubMed: 26909576] 
17. Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, et al. Whole genomes redefine 
the mutational landscape of pancreatic cancer. Nature. 2015; 518:495–501. [PubMed: 25719666] 
18. Harada T, Chelala C, Bhakta V, Chaplin T, Caulee K, Baril P, et al. Genome-wide DNA copy 
number analysis in pancreatic cancer using high-density single nucleotide polymorphism arrays. 
Oncogene. 2008; 27:1951–60. [PubMed: 17952125] 
19. Zhu Y, Qiu P, Ji Y. TCGA-assembler: open-source software for retrieving and processing TCGA 
data. Nat Methods. 2014; 11:599–600. [PubMed: 24874569] 
20. Wan YW, Allen GI, Liu Z. TCGA2STAT: simple TCGA data access for integrated statistical 
analysis in R. Bioinformatics (Oxford, England). 2015; 32:952–4.
21. Kirby MK, Ramaker RC, Gertz J, Davis NS, Johnston BE, Oliver PG, et al. RNA sequencing of 
pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term 
survival and reveals a role for ANGPTL4. Molecular oncology. 2016; 10:1169–82. [PubMed: 
27282075] 
22. Huang H, Dong X, Kang MX, Xu B, Chen Y, Zhang B, et al. Novel blood biomarkers of pancreatic 
cancer-associated diabetes mellitus identified by peripheral blood-based gene expression profiles. 
The American journal of gastroenterology. 2010; 105:1661–9. [PubMed: 20571492] 
23. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential 
expression analysis of digital gene expression data. Bioinformatics (Oxford, England). 2010; 
26:139–40.
24. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set 
enrichment analysis: a knowledge-based approach for interpreting genome-wide expression 
profiles. Proc Natl Acad Sci U S A. 2005; 102:15545–50. [PubMed: 16199517] 
25. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates 
sensitive and confident localization of the targets of focal somatic copy-number alteration in 
human cancers. Genome Biol. 2011; 12:R41. [PubMed: 21527027] 
26. Hu T, Zhang W, Fan Z, Sun G, Likhodi S, Randell E, et al. Metabolomics Differential Correlation 
Network Analysis of Osteoarthritis. Pac Symp Biocomput. 2016; 21:120–31. [PubMed: 26776179] 
27. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate - a Practical and Powerful 
Approach to Multiple Testing. Journal of the Royal Statistical Society Series B-Methodological. 
1995; 57:289–300.
28. Hwang A, Narayan V, Yang YX. Type 2 diabetes mellitus and survival in pancreatic 
adenocarcinoma: a retrospective cohort study. Cancer. 2013; 119:404–10. [PubMed: 23292900] 
29. Nakamura S, Sakata S, Kojima N, Komaki T, Matsuda M, Miura K. Serum thyroglobulin 
concentration in patients with diabetes mellitus. Endocrinol Jpn. 1987; 34:473–8. [PubMed: 
3315639] 
30. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. 
Annu Rev Immunol. 2008; 26:677–704. [PubMed: 18173375] 
31. Hoos A. Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. 
Nature reviews. 2016; 15:235–47.
Yan et al. Page 12
Clin Cancer Res. Author manuscript; available in PMC 2018 October 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
32. Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, et al. Targeting CXCL12 from 
FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in 
pancreatic cancer. Proc Natl Acad Sci U S A. 2013; 110:20212–7. [PubMed: 24277834] 
33. Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, et al. The combined effects 
of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and 
induce a regulatory phenotype in naive T cells. J Immunol. 2006; 176:6752–61. [PubMed: 
16709834] 
34. Silina K, Zayakin P, Kalnina Z, Ivanova L, Meistere I, Endzelins E, et al. Sperm-associated 
antigens as targets for cancer immunotherapy: expression pattern and humoral immune response in 
cancer patients. J Immunother. 2011; 34:28–44. [PubMed: 21150711] 
35. Teng DH, Perry WL 3rd, Hogan JK, Baumgard M, Bell R, Berry S, et al. Human mitogen-activated 
protein kinase kinase 4 as a candidate tumor suppressor. Cancer Res. 1997; 57:4177–82. [PubMed: 
9331070] 
36. Suzuki A, Leland P, Joshi BH, Puri RK. Targeting of IL-4 and IL-13 receptors for cancer therapy. 
Cytokine. 2015; 75:79–88. [PubMed: 26088753] 
37. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes 
and cancer: a consensus report. Diabetes care. 2010; 33:1674–85. [PubMed: 20587728] 
38. Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB 3rd, et al. Impact of 
diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol. 2003; 21:433–40. 
[PubMed: 12560431] 
39. Hart PA, Law RJ, Frank RD, Bamlet WR, Burch PA, Petersen GM, et al. Impact of diabetes 
mellitus on clinical outcomes in patients undergoing surgical resection for pancreatic cancer: a 
retrospective, cohort study. The American journal of gastroenterology. 2014; 109:1484–92. 
[PubMed: 25070053] 
40. Amedei A, Niccolai E, Prisco D. Pancreatic cancer: role of the immune system in cancer 
progression and vaccine-based immunotherapy. Hum Vaccin Immunother. 2014; 10:3354–68. 
[PubMed: 25483688] 
41. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 
2012; 12:252–64. [PubMed: 22437870] 
42. Birnbaum DJ, Finetti P, Lopresti A, Gilabert M, Poizat F, Turrini O, et al. Prognostic value of 
PDL1 expression in pancreatic cancer. Oncotarget. 2016; 7:71198–210. [PubMed: 27589570] 
43. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of “tumor escape” 
phenotypes. Nat Immunol. 2002; 3:999–1005. [PubMed: 12407407] 
44. Witkiewicz A, Williams TK, Cozzitorto J, Durkan B, Showalter SL, Yeo CJ, et al. Expression of 
indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T 
cells to avoid immune detection. J Am Coll Surg. 2008; 206:849–54. discussion 54-6. [PubMed: 
18471709] 
45. Mohindra NA, Kircher SM, Nimeiri HS, Benson A, Rademaker A, Alonso E, et al. Results of the 
phase Ib study of ipilimumab and gemcitabine for advanced pancreas cancer. J Clin Oncol. 2015; 
33
46. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-
PD-L1 antibody in patients with advanced cancer. The New England journal of medicine. 2012; 
366:2455–65. [PubMed: 22658128] 
47. Koido S, Homma S, Takahara A, Namiki Y, Tsukinaga S, Mitobe J, et al. Current 
immunotherapeutic approaches in pancreatic cancer. Clinical & developmental immunology. 2011; 
2011:267539. [PubMed: 21922022] 
48. Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, et al. Phase 2 trial of single 
agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. 
Journal of immunotherapy. 2010; 33:828–33. [PubMed: 20842054] 
49. Kimura Y, Tsukada J, Tomoda T, Takahashi H, Imai K, Shimamura K, et al. Clinical and 
immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine 
and/or S-1 in patients with advanced pancreatic carcinoma. Pancreas. 2012; 41:195–205. 
[PubMed: 21792083] 
Yan et al. Page 13
Clin Cancer Res. Author manuscript; available in PMC 2018 October 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
50. Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ, et al. Phase III study 
comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic 
adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol. 2010; 
28:3605–10. [PubMed: 20606093] 
Yan et al. Page 14
Clin Cancer Res. Author manuscript; available in PMC 2018 October 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Translational Relevance
Pancreatic adenocarcinomas (PAAD) and diabetes share their origin in the same organ 
and often occur concurrently. A list of immunotherapy agents deliver benefits for 
individuals with many types of cancer, but not PAAD. The reasons for this remain 
unclear. Here, we conduct the differential molecular profile analysis in PAAD with/out 
diabetes from the TCGA cohort, which reveals the impact of diabetes on 
immunodeficiency. To the best of our knowledge, this is the first comparative genomics 
study that provides novel molecular insight on the impact of immunotherapy for PAAD, 
which will help identify individuals who are most likely to benefit from treatment as well 
as facilitate in identification of optimal patient populations for immunotherapy clinical 
trials.
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Figure 1. 
Differential gene expression and pathway regulation in subjects with PAAD with/out 
diabetes. Overall pattern of differential gene expression in PAAD with/out diabetes is shown 
by volcano plot (A). Each point in the plot represents a gene and the gene over-expressed in 
PAAD with diabetes has log2 fold change larger than 0 which lies in the right-hand side of 
the plot (A). Genes in the top right corner are up-regulated with a small p value in PAAD 
with diabetes vs. without diabetes (A). Expression levels of PD-1 (B), CTLA4 (C), CXCL12 
(D) and IDO (E) in PAAD with/out diabetes are provided in violin plot. In the violin plot, 
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the black dot represents the median; the thick white bar in the center represents the 
interquartile range and the black line represents the 95% confidence interval. A wider 
section of the violin plot means a higher density of points. Scatter plot of normalized 
enrichment score (NES) and nominal p-value (red), family wise-error rate p-value (FWER p-
value; green), false discovery rate q-value (FDR q-value; black) is used to show differential 
pathway regulation in diabetes (F). Each point in the plot (F) represents a pathway from 
GSEA analysis. The pathway having a small p-value and large enrichment score in PAAD 
with diabetes lies in the right-bottom of the plot (F). Bar plot for significant pathways with 
FDR q-values less than 0.05 (G).
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Figure 2. 
SCNA analysis in PAAD with/out diabetes. Significance of SCNA was tested by GISTIC 2.0 
and the genomic regions showing significant amplification are provided (A). The dash green 
line indicates the q-value less than 0.05 (A). A venn diagram is used to show the number of 
genes within genomic regions showing significant amplification as well as the overlay with 
significant genes identified from RNAseq (B). Each circle in the venn diagram represents 
one set and the number in the overlaid area represents the common genes between the sets 
(B). There are 4 genes (pink area) overlaid between amplification regions in non-diabetic 
subgroup of SCNA analysis and down-regulation in diabetic subgroup of RNAseq analysis 
(B). The genomic regions with significant deletion in PAAD with/out diabetes (C). Number 
of genes within the significant deletion and the overlay with differentially expressed genes 
from RNAseq (D). The number of genes within the deletion regions in the diabetic subgroup 
is 5 (the sum of number in “Del_WiDia” set) and in non-diabetic subgroup is 2137 (the sum 
of numbers in “Del_WoDia” set) (D). There are 3 genes within the significant deletion 
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regions which are common in both diabetic and non-diabetic subgroups (orange area) (D). 
There are 34 genes (blue area) overlaid between the deletion regions in non-diabetic 
subgroup of SCNA analysis and up-regulation in diabetic subgroup of RNAseq analysis (D).
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Figure 3. 
Integration of epigenetic change and gene expression in PAAD with/out diabetes. Regulation 
of gene expression by miRNA is analyzed by microRNA target filter in IPA and plot as 
network in R (version 3.2.0) (A). miRNA is denoted in green (down-regulated in PAAD with 
diabetes) and pink (up-regulated in PAAD with diabetes) nodes. Up-regulated gene in PAAD 
with diabetes identified from RNAseq is colored in red and the down-regulated one is in 
blue (A). The differential correlation profile between gene and its DNA methylation in 
PAAD with/out diabetes is provided (B). Each point represents a gene and the ones in purple 
are significantly different from permutation test (B). The correlation coefficient value 
between gene expression and beta value of DNA methylation in PAAD with diabetes is 
plotted in the X-axis (B). The dash lines represent zero correlation coefficients (B). The 
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differential correlation of ITGB7 and its DNA methylation in PAAD with/out diabetes is 
shown in scatter plot with each point representing a sample(C). The differential correlation 
of SPAG6 and its DNA methylation in PAAD with/out diabetes is shown in scatter plot (D).
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Figure 4. 
Somatic mutation analysis in PAAD with/out diabetes. Log odds ratio of diabetes having 
mutation as well as p values derived from Fisher's Exact test is shown in scatter plot (A). 
Each point in the plot represents a mutant gene (A). To prevent over-plotting, the points are 
jittered and use of color to denote extent of over-plotting (Blue for lightest and Red for 
heaviest). A heatmap is to show the mutation pattern of the selected genes (B). Magenta 
color in heatmap means the mutation is detected (B). Bar plot above heatmap denotes the 
number of mutations occurring for each subject and left side bar plot is to show number of 
subjects having a mutation for each gene. The details of mutation occurred in MAP2K4 and 
IL4R are provided (C).
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Table 1
Baseline characteristics of participants in the PAAD with/out diabetes
PAAD without Diabetes 
(N=111)
PAAD with Diabetes 
(N=38) Pvalue
Age_at_initial_pathologic_diagnosis, mean(sd) 63.66(11.92) 65.95(9) 0.275
Maximum_tumor_dimension, mean(sd) 3.8(1.57) 3.73(1.23) 0.816
Gender, N(%)
0.135
Female 54(80.6%) 13(19.4%)
Male 57(69.51%) 25(30.49%)
Race, N(%)
0.217
White 92(71.32%) 37(28.68%)
Asian 10(90.91%) 1(9.09)
Black or African American 5(100%) 0(0%)
Unknown or Not Evaluated(Not used for statistical testing) 4(100%) 0(0%)
Ethnicity, N(%)
1
Hispanic or Latino 2(66.67%) 1(33.33%)
Not Hispanic or Latino 76(71.03%) 31(28.97%)
Unknown or Not Evaluated or Not Evaluated(Not used for statistical testing) 33(84.62%) 6(15.38%)
History_other_malignancy, N(%)
0.762
Yes 13(81.25%) 3(18.75%)
No 98(73.68%) 35(26.32%)
Pathologic_stage, N(%)
0.443
Stage I 14(77.78%) 4(22.22%)
Stage II 94(75.2%) (31(24.8%)
Stage III 2(66.67%) 1(33.33%)
Stage IV 0(0%) 1(100%)
Not Available or Discrepancy(Not used for statistical testing) 1(50%) 1(50%)
Smoking, N(%)
0.058
Current smoker 51(66.23%) 26(33.77%)
Lifelong Non-smoker 51(80.95%) 12(19.05%)
Unknown(Not used for statistical testing) 9(100%) 0(0%)
Alcohol_history_documented, N(%)
0.543
Yes 71(71.72%) 28(28.28%)
No 36(78.26%) 10(21.74%)
Unknown(Not used for statistical testing) 4(100%) 0(0%)
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Table 2
Pathways with FDR q value less than 0.10
Gene Set Size NES NOM.p.val FDR.q.val
KEGG_HEMATOPOIETIC_CELL_LINEAGE 81 2.037 0.0009 0.0406
KEGG_PRIMARY_IMMUNODEFICIENCY 35 2.023 <0.0001 0.0442
KEGG_T_CELL_RECEPTOR_SIGNALING_PATHWAY 108 2.091 <0.0001 0.048
PID_CD8TCRPATHWAY 52 2.038 0.0004 0.0485
BIOCARTA_NKT_PATHWAY 29 1.983 0.0008 0.0498
PID_CD8TCRDOWNSTREAMPATHWAY 64 2.049 0.0005 0.0503
KEGG_TYPE_I_DIABETES_MELLITUS 23 2.063 <0.0001 0.0517
PID_IL12_2PATHWAY 60 2.127 <0.0001 0.0525
PID_IL12_STAT4PATHWAY 31 1.97 0.002 0.0539
SIG_BCR_SIGNALING_PATHWAY 46 1.983 0.0028 0.0546
REACTOME_COSTIMULATION_BY_THE_CD28 _FAMILY 55 1.998 0.0024 0.055
PID_TCR_PATHWAY 64 1.947 0.002 0.0562
KEGG_CELL_ADHESION_MOLECULES_CAMS 113 1.956 0.0027 0.0562
KEGG_GRAFT_VERSUS_HOST_DISEASE 19 1.986 <0.0001 0.0574
KEGG_CHEMOKINE_SIGNALING_PATHWAY 188 1.949 0.0017 0.0576
KEGG_INTESTINAL_IMMUNE_NETWORK_FOR_IGA _PRODUCTION 34 1.957 0.0055 0.0598
KEGG_NATURAL_KILLER_CELL_MEDIATED _CYTOTOXICITY 127 1.936 0.0027 0.0613
KEGG_AUTOIMMUNE_THYROID_DISEASE 32 1.929 0.0016 0.0637
KEGG_CYTOKINE_CYTOKINE_RECEPTOR _INTERACTION 264 1.919 0.0019 0.0686
KEGG_ALLOGRAFT_REJECTION 17 1.905 0.0029 0.0702
REACTOME_CHEMOKINE_RECEPTORS_BIND _CHEMOKINES 55 1.911 0.0056 0.0715
BIOCARTA_IL12_PATHWAY 21 1.906 0.0013 0.0722
REACTOME_CD28_DEPENDENT_PI3K_AKT _SIGNALING 21 1.892 0.0028 0.0752
ST_T_CELL_SIGNAL_TRANSDUCTION 44 1.895 0.0086 0.076
BIOCARTA_TH1TH2_PATHWAY 17 1.881 0.0029 0.0817
REACTOME_GENERATION_OF_SECOND _MESSENGER_MOLECULES 20 1.866 0.0004 0.0924
PID_CD40_PATHWAY 31 1.847 0.0114 0.0925
PID_IL2_1PATHWAY 55 1.847 0.0096 0.0952
BIOCARTA_DC_PATHWAY 22 1.859 0.0063 0.096
REACTOME_TCR_SIGNALING 44 1.854 0.0085 0.098
PID_FCER1PATHWAY 61 1.851 0.0087 0.0983
BIOCARTA_LAIR_PATHWAY 17 1.847 0.0055 0.0984
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